Algen Biotechnologies Company Profile

Background

Overview

Algen Biotechnologies is a biotechnology company specializing in therapeutic drug discovery through advanced CRISPR gene modulation and artificial intelligence (AI). Founded in 2018, the company is headquartered in San Francisco, California. Algen's mission is to revolutionize the identification and development of novel therapeutics by leveraging cutting-edge technologies to decode complex gene networks. The company focuses on diseases with high unmet medical needs, including various cancers and chronic inflammatory conditions. Algen's vision is to create a smarter drug discovery platform that integrates functional genomics with AI to accelerate the development of next-generation therapies.

Industry Significance

Algen operates at the intersection of biotechnology and artificial intelligence, a rapidly evolving sector with significant potential to transform drug discovery processes. By combining CRISPR-based gene modulation with AI-driven analysis, Algen aims to enhance the precision and efficiency of identifying therapeutic targets, thereby contributing to the advancement of personalized medicine. The company's innovative approach positions it as a notable player in the biotech industry, particularly in the realm of functional genomics and AI applications in drug discovery.

Key Strategic Focus

Core Objectives

Algen's strategic focus centers on developing a comprehensive platform that integrates CRISPR gene modulation with AI to map disease pathways at the single-cell level. This approach aims to uncover disease-driving RNA messages, facilitating the identification of novel therapeutic targets and accelerating the development of effective treatments for complex diseases.

Areas of Specialization

The company specializes in functional genomics, utilizing CRISPR technology for precise gene modulation, and AI for analyzing large-scale biological data. Algen's expertise lies in understanding gene interactions and biological pathways to inform drug discovery processes.

Key Technologies Utilized

• AlgenCRISPR: A proprietary, next-generation CRISPR system that offers robust, fine-tuned, and precise gene modulation to deconvolute complex biology.

• AlgenBrain™: An AI-driven platform that models disease progression by capturing dynamic RNA changes in human, disease-relevant cell types, linking them to functional outcomes and therapeutic potential through high-throughput gene modulation.

Primary Markets Targeted

Algen focuses on therapeutic areas with high unmet needs, including oncology, immunology, and metabolic disorders. The company's technologies are designed to accelerate drug discovery in these fields by providing deeper insights into disease mechanisms and potential therapeutic interventions.

Financials and Funding

Funding History

Algen Biotechnologies has secured funding through multiple rounds, including grants and seed investments. Notably, in September 2021, the company received a grant of $350,000 from the U.S. Department of Health and Human Services (HHS). In October 2018, Algen raised seed funding from Illumina, a leader in genomics analysis technologies.

Recent Funding Rounds

In October 2025, Algen entered a multi-target partnership with AstraZeneca, valued at up to $555 million. This agreement includes upfront payments and potential future milestones, reflecting the strategic value and potential of Algen's technologies in advancing drug discovery.

Notable Investors

• Illumina: A global leader in genomics analysis technologies, Illumina invested in Algen during its seed funding round in 2018.

• U.S. Department of Health and Human Services (HHS): Provided a grant of $350,000 to Algen in September 2021.

• AstraZeneca: Entered into a multi-target partnership with Algen in October 2025, valued at up to $555 million.

Utilization of Capital

The funds raised are intended to support the advancement of Algen's proprietary platforms, AlgenCRISPR and AlgenBrain™, and to facilitate the development of novel therapeutics in collaboration with strategic partners. The partnership with AstraZeneca, in particular, is expected to accelerate the discovery of new therapeutic targets in immunology.

Pipeline Development

Key Pipeline Candidates

Algen's pipeline includes multiple programs across oncology, immunology, and metabolic disorders. The lead asset is an anti-cancer agent that is nearing clinical trials.

Stages of Development

The lead anti-cancer agent is in the preclinical stage, with plans to advance into clinical trials. Other pipeline candidates are in various stages of development, leveraging Algen's platforms to identify and validate therapeutic targets.

Target Conditions

The pipeline targets diseases with high unmet medical needs, including various cancers, chronic inflammatory conditions, and metabolic disorders.

Anticipated Milestones

Key milestones include the initiation of clinical trials for the lead anti-cancer agent and the advancement of other pipeline candidates through preclinical and clinical development stages.

Technological Platform and Innovation

Proprietary Technologies

• AlgenCRISPR: A next-generation CRISPR system that enables precise gene modulation, facilitating the deconstruction of complex biological systems.

• AlgenBrain™: An AI-driven platform that models disease progression by capturing dynamic RNA changes in human, disease-relevant cell types, linking them to functional outcomes and therapeutic potential through high-throughput gene modulation.

Significant Scientific Methods

• Single-Cell Gene Modulation: Utilizing CRISPR technology to modulate genes at the single-cell level, providing insights into cellular responses and disease mechanisms.

• AI-Driven Data Analysis: Employing deep learning models to analyze large-scale biological data, identifying patterns and potential therapeutic targets.

AI-Driven Capabilities

Algen's integration of AI with functional genomics allows for the modeling of disease progression and the identification of novel therapeutic targets, enhancing the precision and efficiency of drug discovery processes.

Leadership Team

Key Executives

• Chun-Hao Huang, Ph.D.: CEO & Co-Founder. Dr. Huang is a bioengineer who co-founded Algen Biotechnologies after his postdoctoral work in the lab of Nobel laureate Jennifer Doudna at UC Berkeley.

• Christine Du: CBO & Co-Founder. Ms. Du is a biotech commercialization expert who co-founded Algen Biotechnologies, bringing expertise in business development and strategic partnerships.

• Jeffrey P. Whitten, Ph.D.: Chief Scientific Officer. Dr. Whitten has experience in preclinical and CMC development, having previously served as Senior Vice President at Turning Point Therapeutics.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in the areas of functional genomics and AI-driven drug discovery, is experiencing rapid growth. Companies are increasingly leveraging advanced technologies to accelerate the identification of therapeutic targets and the development of personalized medicines.

Competitor Analysis

Algen Biotechnologies operates in a competitive landscape with several notable companies:

• BridgeBio: Focuses on developing medicines for genetic diseases.

• Spark Therapeutics: Specializes in gene therapies for genetic diseases.

• Alnylam Pharmaceuticals: Develops RNA interference therapies.

• ATAI Life Sciences: Focuses on mental health treatments.

• Insitro: Combines machine learning with biology to discover new drugs.

These competitors vary in their technological approaches and therapeutic focuses but share the common goal of advancing drug discovery through innovative methods.

Strategic Collaborations and Partnerships

Algen's partnership with AstraZeneca is a significant collaboration, providing access to AstraZeneca's expertise in translational science and clinical development. This alliance aims to accelerate the discovery of novel therapeutic targets in immunology.

Operational Insights

Algen's integration of CRISPR technology with AI-driven data analysis offers a distinct competitive advantage, enabling precise gene modulation and comprehensive disease modeling. This approach enhances the efficiency and accuracy of drug discovery processes, positioning Algen favorably in the competitive landscape.